Beyond Dose Escalation in Glioblastoma: Lessons Learned from INTRAGO-II and the Case for Targeting Tumor Biology.

Layer JP, Schneider M, Hölzel M, Herrlinger U, Winkler F

Open source

DOI
10.1093/neuonc/noag166
Published
2026 Sep 17
Container
Neuro-oncology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/noag166,
  title = {Beyond Dose Escalation in Glioblastoma: Lessons Learned from INTRAGO-II and the Case for Targeting Tumor Biology.},
  author = {Layer JP and Schneider M and Hölzel M and Herrlinger U and Winkler F},
  year = {2026},
  journal = {Neuro-oncology},
  doi = {10.1093/neuonc/noag166},
  url = {https://doi.org/10.1093/neuonc/noag166}
}

RIS

TY  - JOUR
TI  - Beyond Dose Escalation in Glioblastoma: Lessons Learned from INTRAGO-II and the Case for Targeting Tumor Biology.
AU  - Layer JP
AU  - Schneider M
AU  - Hölzel M
AU  - Herrlinger U
AU  - Winkler F
PY  - 2026
JO  - Neuro-oncology
DO  - 10.1093/neuonc/noag166
UR  - https://doi.org/10.1093/neuonc/noag166
ER  - 

APA

JP, L., M, S., M, H., U, H., & F, W. (2026). Beyond Dose Escalation in Glioblastoma: Lessons Learned from INTRAGO-II and the Case for Targeting Tumor Biology.. Neuro-oncology. https://doi.org/10.1093/neuonc/noag166

Source records